Cardiomatics Seed

Select partners: Tessinum, Augustinum, doctoRees, Herz- und Gefäßpraxis am Druidenstein, Internistisch / Hausärztliche Gemeinschaftspraxis, PZU Zdrowie.
Primary contact
Wojciecha Weissa 7
31-339 Krakow
Poland
+48 790 261 534
Wojciecha Weissa 7
31-339 Krakow
Poland
+48 790 261 534
Funding 💰
Total
€4.4M
Last round
🔗
€2.7
August 20, 2021.
August 20, 2021.
Select investors Kaya, Poland’s National Center for Research & Development, Nina Capital, Nova Capital, Innovation Nest
Key people 🧑🤝🧑
- Rafał Samborski - CEO
- Mariusz Mąsior - CTO
- Katarzyna Barczewska - Head of R&D
- Przemyslaw Tadla - Head of Partnerships
- Krzysztof Homa - Business Development
Highlights ⭐
- Pan-European reach: Cardiomatics' software is being used by more than 700 customers in 10+ countries, including Switzerland, Denmark, Germany and Poland.
- Rock-solid tech: The company's algorithms have been trained from more than 10 billion heartbeats from approximately 100,000 patients and is systematically growing.
- EU's first approved AI medical device: Cardiomatics was the first AI-based solution approved as a medical device in Europe.
- Expansion plans: The company aims to further expand across Europe and eventually obtain FDA certification and enter the US market.
Video ▶️
Awards & Recognitions 🏆
- 2021 WorldFestival Top 50 Startup Award Winners 🔗
Quotes 💬
“
In the field of cardiac electrophysiology, Cardiomatics facilitates and speeds up the diagnosis of arrhythmia.
— Paweł Balsam, BA, MD, PhD, FESC
“
It used to be very time-consuming to analyze long-term recordings with our conventional Holter software. Using Cardiomatics, the interpretation is now fast and reliable.
— Dr. med. Ulrich Ingold, Kardiologie Interlaken-Unterseen, Switzerland
“
The web-based platform is very simple and user-friendly. After uploading the raw signal of the ECG, we get access to a detailed report within a few hours. In a clinical routine, this can save a lot of time compared to the time-consuming analysis of Holter recordings with conventional Holter software.
— Prof. Michael Kühne, MD, Head of Clinic Atrial Fibrillation, University Hospital Basel, Switzerland
Last update:
August 16, 2022
Disclaimer: The content on this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances.